“GLIMET” vs “GLYZET / GLYNET”
Laboratories Griffon Pvt Ltd And Anr vs Rajiv Mukul Proprietor Of Zee. | INTERIM APPLICATION NO. 3540 OF 2022 IN COMM IP SUIT NO. 213 OF 2022 | Bombay High Court – 13th January 2026
In a significant ruling reaffirming the heightened scrutiny applicable to pharmaceutical trademarks, the Hon’ble Bombay High Court granted an injunction in favour of the plaintiff’s mark “GLIMET”, restraining the defendants from using the deceptively similar marks “GLYZET” and “GLYNET.”
Factual Background: The dispute arose in the context of anti-diabetic pharmaceutical products, a therapeutic segment where precision in drug identification is critical. The plaintiff, proprietor of the mark “GLIMET,” had been using the mark in relation to medicines for the treatment of diabetes and had built a degree of recognition in the market. The defendants had earlier given undertakings to the Court agreeing not to use marks that were deceptively similar to the plaintiff’s mark. Despite such undertakings, the defendants adopted and continued to use the marks “GLYZET” and “GLYNET,” prompting the plaintiff to initiate contempt and infringement proceedings.
Court’s Analysis: The Court undertook a phonetic, visual, and structural comparison of the marks and observed that:
- All marks shared the common prefix “GLY”, which is commonly associated with glucose-related medications.
- The suffixes “MET,” “ZET,” and “NET” were found to be phonetically similar, especially in the context of prescriptions, where handwriting or verbal communication may be unclear.
- The overall structure and cadence of the marks created a real likelihood of confusion, particularly among patients, pharmacists, and medical practitioners.
The Court placed strong reliance on established jurisprudence (including principles from Cadila Healthcare Ltd. v. Cadila Pharmaceuticals Ltd.) which mandates a stricter test in pharmaceutical trademark disputes due to the direct impact on public health.
Aggravating Factors: What made this case particularly serious was the conduct of the defendants:
- Deliberate breach of prior undertakings given to the Court;
- Evidence suggesting dishonest adoption rather than coincidental similarity;
- Continued use of the impugned marks despite being on notice.
Relief and Penalties: In light of these factors, the Hon’ble Court:
- Granted a permanent injunction restraining use of the impugned marks;
- Imposed exemplary costs of ₹50 lakhs, signalling strong judicial disapproval;
- Directed initiation of perjury proceedings, highlighting the seriousness of misleading the Court.
Legal Significance: This decision reinforces several key principles:
- Pharmaceutical trademark disputes are subject to a public interest overlay, where even minimal confusion is unacceptable;
- Courts are willing to impose punitive costs and sanctions where parties act in bad faith;
- Prior undertakings, once breached, significantly weaken a defendant’s case and invite stricter scrutiny.
Further Trademark Developments
“GLIMET” vs “GLYZET / GLYNET”
Laboratories Griffon Pvt Ltd And Anr vs Rajiv Mukul Proprietor Of Zee. | INTERIM APPLICATION NO. 3540 OF 2022 IN COMM IP SUIT NO. 213 OF 2022 | Bombay High Court – 13th January 2026
In a significant ruling reaffirming the heightened scrutiny applicable to pharmaceutical trademarks, the Hon’ble Bombay High Court granted an injunction in favour of the plaintiff’s mark “GLIMET”, restraining the defendants from using the deceptively similar marks “GLYZET” and “GLYNET.”
Factual Background: The dispute arose in the context of anti-diabetic pharmaceutical products, a therapeutic segment where precision in drug identification is critical. The plaintiff, proprietor of the mark “GLIMET,” had been using the mark in relation to medicines for the treatment of diabetes and had built a degree of recognition in the market. The defendants had earlier given undertakings to the Court agreeing not to use marks that were deceptively similar to the plaintiff’s mark. Despite such undertakings, the defendants adopted and continued to use the marks “GLYZET” and “GLYNET,” prompting the plaintiff to initiate contempt and infringement proceedings.
Court’s Analysis: The Court undertook a phonetic, visual, and structural comparison of the marks and observed that:
- All marks shared the common prefix “GLY”, which is commonly associated with glucose-related medications.
- The suffixes “MET,” “ZET,” and “NET” were found to be phonetically similar, especially in the context of prescriptions, where handwriting or verbal communication may be unclear.
- The overall structure and cadence of the marks created a real likelihood of confusion, particularly among patients, pharmacists, and medical practitioners.
The Court placed strong reliance on established jurisprudence (including principles from Cadila Healthcare Ltd. v. Cadila Pharmaceuticals Ltd.) which mandates a stricter test in pharmaceutical trademark disputes due to the direct impact on public health.
Aggravating Factors: What made this case particularly serious was the conduct of the defendants:
- Deliberate breach of prior undertakings given to the Court;
- Evidence suggesting dishonest adoption rather than coincidental similarity;
- Continued use of the impugned marks despite being on notice.
Relief and Penalties: In light of these factors, the Hon’ble Court:
- Granted a permanent injunction restraining use of the impugned marks;
- Imposed exemplary costs of ₹50 lakhs, signalling strong judicial disapproval;
- Directed initiation of perjury proceedings, highlighting the seriousness of misleading the Court.
Legal Significance: This decision reinforces several key principles:
- Pharmaceutical trademark disputes are subject to a public interest overlay, where even minimal confusion is unacceptable;
- Courts are willing to impose punitive costs and sanctions where parties act in bad faith;
- Prior undertakings, once breached, significantly weaken a defendant’s case and invite stricter scrutiny.
